While it is imperative to note the risk of acute pancreatitis with initiation of a GLP-1 agonist alone, it is crucial to understand the potential risk of GI symptoms and potential for acute pancreatitis when switching between different GLP-1 agonist medications. This evidence concerns the gene GCG and acute pancreatitis.